Antisense oligonucleotides: Target validation and development of systemically delivered therapeutic nanoparticles

Methods in Molecular Biology

Volumn 361, Issue , 2007, Pages 163-185

  Zhang, Chuanbo ^a   Pei, Jin ^a   Kumar, Deepak ^a   Sakabe, Isamu ^a   Boudreau, Howard E ^a   Gokhale, Prafulla C ^a   Kasid, Usha N ^a  

^a NONE

Author keywords

Antisense oligonucleotides; Cancer therapy; Chemotherapeutic drugs; Liposomes; Preclinical validation; Radiation; Raf 1

Indexed keywords

MUS; MUS MUSCULUS;

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; DRUG CARRIER; LERAFAON; NANOPARTICLE; NUCLEOTIDE; OBLIMERSEN; OLIGODEOXYRIBONUCLEOTIDE; PROTEIN BCL 2; RAF PROTEIN;

ANIMAL; BIOSYNTHESIS; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE; MULTIMODALITY CANCER THERAPY; NEOPLASM; NUDE MOUSE; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DRUG CARRIERS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; NANOPARTICLES; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-RAF; THIONUCLEOTIDES;

EID: 36549042404     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1385/1-59745-208-4:163     Document Type: Article

References (83)

1. Zamecnik, P. C. and Stephenson, M. L. (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 75, 280-284.
2. Kasid, U., Pfeifer, A., Brennan, T., et al. (1989) Effect of antisense c-raf-l on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science 243, 1354-1356.
3. Pirrollo, K. F., Rait, A., Sleer, L. S., and Chang, E. H. (2003) Antisense therapeutics: from theory to clinical practice. Pharmacol. Ther. 99, 55-77.
4. Kurreck, J. (2003) Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 270, 1628-1644.
5. Kasid, U. and Dritschilo, A. (2003) RAF antisense oligonucleotide as a tumor radiosensitizer. Oncogene 11, 5876-5884.
6. Agrawal, S. and Kandimalla, E. R. (2004) Antisense and siRNA as agonists of Toll-like receptors. Nat. Biotechnol. 11, 1533-1537.
7. Crooke, S. T. (2004) Progress in antisense technology. Annu. Rev. Med. 55, 61-95.
8. Gleave, M. E. and Monia, B. P. (2005) Antisense therapy for cancer. Nat. Rev. Cancer 5, 468-479.
9. Monia, B. P., Johnston, J. F., Geiger, T., Muller, M., and Fabbro, D. (1996) Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. 6, 668-675.
10. Mullen, P., McPhillips, G., MacLeod, K., Monia, B., Smyth, J. F., and Langdon, S. P. (2004) Antisense oligonucleotide targeting of Raf-1: Importance of Raf-1: mRNA expression levels and Raf-1-dependent signaling in determining growth response in ovarian cancer. Clin. Cancer Res. 10, 2100-2108.
11. Williams, N. G. and Roberts, T. M. (1994) Signal transduction pathways involving the Raf proto-oncogene. Cancer Metastasis Rev. 13, 105-116.
12. Kasid, U., Suy, S., Dent, P., Ray, S., Whiteside, T. L., and Sturgill, T. W. (1996) Activation of Raf by ionizing radiation. Nature 382, 813-816.
13. Suy, S., Anderson, W B., Dent, P., Chang, E., and Kasid, U. (1997) Association of Grb2 with Sos and Ras with Raf-1 upon gamma irradiation of breast cancer cells. Oncogene 15, 53-61.
14. Le Mellay, V., Houben, R., Troppmair, J., et al. (2002) Regulation of glycolysis by RafStress-responsive protein serine/threonine kinases. Adv. Enzyme. Regul. 42, 317-332.
15. Patel, S., Wang, E -H., Whiteside, T. L., and Kasid, U. (1997) Constitutive modulation of Raf-1 protein kinase is associated with differential gene expression of several known and unknown genes. Mol. Med. 3, 674-685.
16. Kasid, U. (2001) Raf-1 protein kinase, signal transduction, and targeted intervention of radiation response. Exp. Biol. Med. 116, 624-625.
17. Kasid, U. and Suy, S. (1998) Stress-responsive signal transduction: emerging concepts and biological significance. In: Apoptosis Genes, (Potten, C. S., Booth, C., and Wilson, J., eds.), Kluwer Academic Publishers, Boston, MA, pp. 85-118.
18. Odabaei, G., Chatterjee, D., Jazirehi, A. R., Goodglick, L., Yeung, K., and Bonavida, B. (2004) Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv. Cancer Res. 91, 169-200.
19. Hindley, A. and Kolch, W. (2002) Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases. J. Cell Sci. 115, 1575-1581.
20. Rasouli-Nia, A., Liu, D., Perdue, S., and Britten, R. A. (1998) High Raf-1 kinase activity protects human tumor cells against paclitaxel-induced cytotoxicity. Clin. Cancer Res. 4, 1111-1116.
21. Weinstein-Oppenheimer, C. R., Henriquez-Roldan, C. F., Davis, J. M., et al. (2001) Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin. Cancer Res. 1, 2898-2907.
22. Nimmanapalli, R., O'Bryan, E., Kuhn, D., Yamaguchi, H., Wang, H. G., and Bhalla, K. N. (2003) Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-XL, and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases. Blood 102, 269-275.
23. Pfeifer, A., Mark, G., Leung, S., Dougherty, M., Spillare, E., and Kasid, U. (1998) Effects of c-raf-1 and c-myc expression on radiation response in an in vitro model of human small-cell-lung-carcinoma. Biochem. Biophy. Res. Comm. 252, 481-486.
24. Tang, W. Y., Chau, S. P., Tsang, W. P., Kong, S. K., and Kwok, T. T. (2004) The role of Raf-1 in radiation resistance of human hepatocellular carcinoma Hep G2 cells. Oncol. Rep. 12, 1349-1354.
25. Pal, A., Ahmad, A., Khan, S., et al. (2005) Systemic delivery of RafsiRNA using cationic cardiolipin liposome silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int. J. Oncology. 26, 1087-1091.
26. Gokhale, P. C., Zhang, C., Newsome, J., et al. (2002) Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome (LErafAON). Clin. Cancer Res. 8, 3611-3621.
27. Mewani, R. R., Tang, W., Rahman, A., et al. (2004) Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped endsmodified raf antisense oligonucleotide against human prostate, lung and breast tumor models. Int. J. One. 24, 1181-1188.
28. Pei, J., Zhang, C., Gokhale, P. C., et al. (2004) Combination with liposomeentrapped, ends-modified raf antisense oligonucleotide (LEraf AON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel, and gemcitabine. Anti-Cancer Drugs 15, 243-253.
29. Rudin, C. M., Marshall, J. L., Huang, C. H., et al. (2004) Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin. Cancer Res. 10, 7244-7251.
30. Soldatenkov, V. A., Dritschilo, A., Wang, E -H., Olah, Z., Anderson, W. B., and Kasid, U. (1997) Inhibition of Raf-1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation. Can J. Sci. Am. 3, 13-20.
31. Dritschilo, A., Huang, C. H., Fleming, C., et al. (2003) Infusion of liposome-encap-sulated c-raf antisense oligodeoxynucleotide (LEraf AON) during radiation therapy in patients with advanced malignancies: a phase I study. Proceedings of the American Society of Clinical Oncology. 11, p. 224.
32. Lei, Y., Ahmad, A., Sheikh, S., Zhang, A., and Ahmad, I. (2004) Enhanced therapeutic efficacy of a novel liposome-based formulation of c-raf AON in combination with Taxol against human ovarian tumor model in SCID mice. Proc. Am. Assoc. Cancer Res. 45, 147.
33. Steinberg, J. L., Mendelson, D. S., Block, H., et al. (2005) Phase I study of LErafAON-ETU, an easy-to-use formulation of liposome entrapped c-raf antisense oligonucleotide, in advanced cancer patients. J. Clin. Oncol. 23 (Suppl.), 244S.
34. Gokhale, P. C., Soldatenkov, V., Wang, F. -H., Rahman, A., Dritschilo, A., and Kasid, U. (1997) Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implications for gene therapy of radioresistant cancer. Gene Therapy 4, 1289-1299.
35. Gleave, M., Tolcher, A., Miyake, H., et al. (1999) Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxy-nucleotides after castration in the LNCaP prostate tumor model. Clin. Cancer Res. 5, 2891-2898.
36. L expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli. Oncogene 18, 4495-4504.
37. Taylor, J. K., Zhang, Q. Q., Wyatt, J. R., and Dean, N. M. (1999) Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat. Biotechnol. 17, 1097-1100.
38. Zangemeister-Wittke, U., Leech, S. H., Olie, R. A., et al. (2000) A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently indues apoptosis in tumor cells. Clin. Cancer Res. 6, 2547-2555.
39. Simões-Wüst, A. P., Hopkins-Donaldson, S., Sigrist, B., Belyanskaya, L., Stahel, R. A., and Zahgemeister-Wittke, U. (2004) A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis. Oligonucleotides 14, 199-209.
40. Rapozzi, V., Burm, B. E. A., Cogoi, S., et al. (2002) Antiproliferative effect in chronic myeloid leukaemia cells by antisense peptide nucleic acids. Nucleic Acids Res. 30, 3712-3721.
41. Zellweger, T., Miyake, H., Cooper, S., et al. (2001) Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J. Pharmacol. Exp. Ther. 298, 934-940.
42. Park, Y. G., Nesterova, M., Agrawal, S., and Cho-Chung, Y S. (1999) Dual blockade of cyclic AMP response element-(CRE) and AP-1-directed transcription by CRE-ttanscription factor decoy oligonucleotide. J. Biol. Chem. 274, 1573-1580.
43. Aharinejad, S., Paulus, P., Sioud, M., et al. (2004) Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res. 64, 5378-5384.
44. Rait, A. S., Pirollo, K. F., Rait, V., Krygier, J. E., Xiang, L., and Chang, E. H. (2001) Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer. Cancer Gene Ther. 8, 728-739.
45. Shadidi, M. and Sioud, M. (2003) Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells. FEBS J. 17, 256-258.
46. Thallinger, C., Wolschek, M. F., Maierhofer, H., et al. (2004) Mcl-1 is a novel therapeutic target for human sarcoma: Synergistic inhibition of human sarcoma xenotransplants by a combination of Mcl-1 antisense oligonucleotides with low-dose cyclophosphamide. Clin. Cancer Res. 10, 4185-4191.
47. Zhang, Z., Wang, H., Prasad, G., et al. (2004) Radiosensitization by antisense antiMDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin. Cancer Res. 10, 1263-1273.
48. Shiraishi, T. and Nielsen, P. E. (2004) Down-regulation of MDM2 and activation of p53 in human cancer cells by antisense 9-aminoacridine-PNA (peptide nucleic acid) conjugates. Nucleic Acids Res. 32, 4893-4902.
49. Zupi, G., Scarsella, M., Semple, S. C., Mottolese, M., Natali, P. G., and Leonetti, C. (2005) Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence. Clin. Cancer Res. 11, 1990-1998.
50. Cuttona, G., Carpaneto, E. M., Ponezanelli, A., et al. (2003) Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the Eμ enhancer. Cancer Res. 63, 6144-6148.
51. Wang, H., Cai, Q., Zeng, X., Yu, D., Agrawall, S., and Zhang, R. (1999) Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIα subunit of protein kinase A after oral administration. Proc. Natl. Acad. Sci. USA 96, 13,989-13,994.
52. Dean, N., Mckay, R., Miraglia, L., et al. (1996) Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-a expression. Cancer Res. 56, 3499-3507.
53. Mologni, L., Marchesi, E., Nielsen, P. E., and Gambacorti-Passerini, C. (2001) Inhibition of promyelocytic leukemia (PML)/retinoic acid receptor-a and PML expression in acute promyelocytic leukemia cells by anti-PML peptide nucleic acid. Cancer Res. 61, 5468-5473.
54. Tanami, H., Imoto, I., Hirasawa, A., et al. (2004) Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. Oncogene 23, 8796-8804.
55. Kasid, U., Olah, Z., Anderson, W., and Dritschilo, A. (1991) Inhibition of c-raf-1 protein kinase activity by antisense phosphorothioate oligonucleotides in human radiation resistant squamous carcinoma cells. Proceedings of the International Congress of Radiation Research, no. P16-03, p. 242.
56. Lee, Y., Vassilakos, A., Feng, N., et al. (2003) GTI-2040, and antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Res. 63, 2802-2811.
57. Elayadi, A. N., Demieville, A., Wancewicz, E. V., Monia, B. P., and Corey, D. R. (2001) Inhibition of telomerase by 2′-O-(2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells. Nucleic Acids Res. 29, 1683-1689.
58. McManus, D. C., Lefebvre, C. A., Cherton-Horvat, G., et al. (2004) Loss of XIAP protein expression by RNAi and antisense approaches sesitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 23, 8105-8117.
59. Agrawal, S., Jiang, Z., Zhao, Q., et al. (1997) Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc. Natl. Acad. Sci. USA 94, 2620-2625.
60. Gokhale, P. C., McRae, D., Monia, B. P., et al. (1999) Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. Antisense Nucleic Acid Drug Dev. 9, 191-201.
61. Johnson, J. L., Guo, W., Zang, J., et al. (2004) Quantification of raf antisense oligonucleotide (rafAON) in biological matrices by LC-MS/MS to support pharmacokinetics of a liposome-entrapped rafAON formulation. Biomed. Chromatogr. 19, 272-278.
62. Rait, A. S., Pirollo, K. F., Xiang, L., Ulick, D., and Chang, E. H. (2002) Tumortargeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. Mol. Med. 8, 475-486.
63. Xu, L., Huang, C. C., Huang, W., et al. (2002) Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol. Cancer Ther. 1, 337-346.
64. Pastorino, F., Brignole, C., Marimpietri, D., et al. (2003) Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin. Cancer Res. 9, 4595-4605.
65. 2- targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. J. Natl. Cancer Inst. 96, 1171-1180.
66. Schwab, G., Chavany, C., Duroux, I., et al. (1994) Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc. Natl. Acad. Sci. USA 91, 10,460-10,464.
67. Lamber, G., Bertrand, J. R., and Fattal, E. (2000) EWS Fil-1 antisense nanocapsules inhibits ewing sarcoma-related tumor in mice. Biochem. Biophys. Res. Commun. 279, 401-406.
68. Leonetti, C., Biroccio, A., Benassi, B., et al. (2001) Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line. Cancer Gene Ther. 8, 459-468.
69. Rudin, C. M., Kozloff, M., Hoffman, P. C., et al. (2004) Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J. Clin. Oncol. 11, 1110-1117.
70. Marshall, J., Chen, H., Yang, D., et al. (2004) A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann. Oncol. 15, 1274-1283.
71. Marcucci, G., Stock, W., Dai, G., et al. (2005) Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: Pharmacokinetics, pharmacodynamics, and clinical activity. J. Clin. Oncol. 23, 3404-3411.
72. Badros, A. Z., Goloubeva, O., Rapoport, A. P., et al. (2005) Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J. Clin. Oncol. 23, 1-11.
73. Tolcher, A. W., Chi, K., Kuhn, J., et al. (2005) A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 11, 3854-3861.
74. Jansen, B., Wacheck, V., Heere-Ress, E., et al. (2000) chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356, 1728-1733.
75. Chen, H. X., Marshall, J. L., Ness, E., et al. (2000) A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors. Clin. Cancer Res. 6, 1259-1266.
76. Goel, S., Desai, K., Bulgaru, A., et al. (2003) A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit a of protein kinase A using a continuous infusion shedule in patients with refractory solid tumors. Clin. Cancer Res. 9, 4069-4076.
77. Mani, S., Goel, S., Nesterova, M., et al. (2003) Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM231) targeted against protein kinase A type I. Ann. N. Y. Acad. Sci. 1002, 252-262.
78. Marshall, J. L., Eisenberg, S. G., Johnson, M. D., et al. (2004) A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer. Clin. Colorectal Cancer 4, 268-274.
79. Mani, S., Rudin, C. M., Kunkel, K., et al. (2002) Phase I clinical and pharmacokinetic study of protein kinase C-α antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin. Cancer Res. 8, 1042-1048.
80. Rao, S., Watkins, D., Cunningham, D., et al. (2004) Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma. Ann. Oncol. 15, 1413-1418.
81. Stevenson, J. P., Yao, K. S., Gallagher, M., et al. (1999) Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J. Clin. Oncol. 17, 2227-2236.
82. Rudin, C. M., Holmlund, J., Fleming, G. F., et al. (2001) Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin. Cancer Res. 2, 1214-1220.
83. Desai, A. A., Schilsky, R. L., Young, A., et al. (2005) A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann. Oncol. 16, 958-965.